TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11393352

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rHuG-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional cyclic chemotherapy with rHuG-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose therapy with rHuG-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rHuG-CSF with or without stem-cell support
Number of subjects: 0
Study: 9003265

Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pneumatic compression devices
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Foot pumps with or without vena caval filters
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: RAPT score
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Color-flow duplex studies
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pulmonary angiograms
Number of subjects: 53
Study: 7939756

Group type: EXPERIMENTAL
Intervention: Paclitaxel (150 mg/m2) followed by Doxorubicin (50 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2) and Doxorubicin (75 mg/m2) alternating every 3 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Paclitaxel alone and Doxorubicin alone
Number of subjects: 12
Study: 3070520

Group type: EXPERIMENTAL
Intervention: DZ 15 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DZ-CR 20 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29896626

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard Wound Management (Standard Dressings)
Number of subjects: 460
Study: 26668177

Group type: EXPERIMENTAL
Intervention: Continuous combined estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 23278670

Group type: EXPERIMENTAL
Intervention: Mg titanate
Number of subjects: 40

Group type: COMPARATOR
Intervention: blasted Mg titanate
Number of subjects: 40
Study: 23683558

Group type: EXPERIMENTAL
Intervention: Intraoperative dobutamine infusion (3 μg/kg per minute or 5 μg/kg per minute)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 60
Study: 20528283

Group type: EXPERIMENTAL
Intervention: Simultaneous Presentation Advertising (SPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical Sequential Advertising (CSA)
Number of subjects: 0
Study: 17720609

Group type: EXPERIMENTAL
Intervention: Endurance-strength training regime for the cervical flexor muscles
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low-load training of the cranio-cervical flexor muscles
Number of subjects: 58
Study: 16784917

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 1510
Study: 12944437

Group type: EXPERIMENTAL
Intervention: Propofol with 70% N(2)O
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol with oxygen‐enriched air (FIO(2) = 0.3)
Number of subjects: 30
Study: 10399801

Group type: EXPERIMENTAL
Intervention: Gentle reperfusion technique
Number of subjects: 14

Group type: COMPARATOR
Intervention: Abrupt reperfusion
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Reperfusion after 20 min
Number of subjects: 14
Study: 8533005

Group type: EXPERIMENTAL
Intervention: Felodipine (Plendil) 5 mg/day
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Combination of felodipine with other antihypertensive drugs (ACE inhibitors, beta blockers, diuretics)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Low doses of aspirin (75 mg/day)
Number of subjects: 797
Study: 2677241

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 40
Study: 339282

Group type: EXPERIMENTAL
Intervention: 2.0 mg 15‐methyl‐PGF2alpha‐methyl ester in a rapid releasing base, administered 6 hours prior to operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.5 mg 15‐methyl‐PGF2alpha‐methyl ester in a slow releasing base, administered 12 hours prior to operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 60
Study: 31594481

Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Suppression of emotional expression
Number of subjects: 317
Study: 31685618

Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 14
Study: 28807486

Group type: EXPERIMENTAL
Intervention: Men living alone or divorced
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Men married
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Women living alone or divorced
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Women married
Number of subjects: 1193
Study: 25998123

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Usual Care plus Voiceover Interactive PowerPoint (UC+VOIPP)
Number of subjects: 51
Study: 24239044

Group type: EXPERIMENTAL
Intervention: TT4 (n=180)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Current standard-of-care (SoC, n=87)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: TT4 (G1 subgroup)
Number of subjects: 267

Group type: COMPARATOR
Intervention: SoC (G1 subgroup)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: TT4 (G2 subgroup)
Number of subjects: 267

Group type: COMPARATOR
Intervention: SoC (G2 subgroup)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: TT4 (G3 subgroup)
Number of subjects: 267

Group type: COMPARATOR
Intervention: SoC (G3 subgroup)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: TT4 (G4 subgroup)
Number of subjects: 267

Group type: COMPARATOR
Intervention: SoC (G4 subgroup)
Number of subjects: 267
Study: 22593697

Group type: EXPERIMENTAL
Intervention: LPNIR plus nerve block (NB) or local block (LB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (NB or LB without LPNIR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (I and C)
Number of subjects: 52
Study: 19948506

Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg if needed)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 150
Study: 17321387

Group type: EXPERIMENTAL
Intervention: Bimanual microphacoemulsification
Number of subjects: 50

Group type: COMPARATOR
Intervention: Coaxial miniphacoemulsification
Number of subjects: 50
Study: 15346702

Group type: EXPERIMENTAL
Intervention: Midazolam 75 microg/kg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 82
Study: 11583479

Group type: EXPERIMENTAL
Intervention: Etoricoxib 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etoricoxib 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etoricoxib 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etoricoxib 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etoricoxib (5-120 mg range)
Number of subjects: 12
Study: 9836104

Group type: EXPERIMENTAL
Intervention: IgA anti‐transglutaminase antibodies by enzyme‐linked immunosorbent assay test
Number of subjects: 41
Study: 8015820

Group type: EXPERIMENTAL
Intervention: BV (Immunomodulation therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 2892450

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29333910

Group type: EXPERIMENTAL
Intervention: Plano contact lenses (CL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fully corrective contact lenses (CL)
Number of subjects: 38
Study: 26474041

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acetaminophen (500 mg twice daily)
Number of subjects: 50
Study: 24471868

Group type: COMPARATOR
Intervention: Alfuzosin 10 mg alone (Group A)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Alfuzosin 10 mg plus Propiverine 10 mg (Group B)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg plus Propiverine 20 mg (Group C)
Number of subjects: 135
Study: 22172432

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20799359

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (80 ppm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (21% O2)
Number of subjects: 18
Study: 18599577

Group type: EXPERIMENTAL
Intervention: Complete proximal MCA recanalization
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Incomplete proximal MCA recanalization
Number of subjects: 44
Study: 19455984

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of 400 ml of ozonized sodium chloride solution (pO3) containing 1.6 microg/ml of O3 twice weekly for 21 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (antibacterial therapy only)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Blood ozonization in combination with antibiotics
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 36
Study: 15938923

Group type: COMPARATOR
Intervention: CPT‐11 90 ‐ 25 mg/m(2) continuous infusion for 10 h and folinic acid (FA) 30 mg x m(‐2) x d(‐1) + 5‐FU 425 mg x m(‐2) x d(‐1) x 2 d continuous infusion for 48 h, every two weeks for a total of no less than six cycles (Group A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CPT‐11 90 ‐ 125 mg/m(2) continuous infusion for 10 h every two weeks for a total of no less than six cycles and capecitabine 1250 mg x m(‐2) x d(‐1) by oral divided into two doses, continuously taken without interruption for three months (Group B)
Number of subjects: 43
Study: 11285130

Group type: EXPERIMENTAL
Intervention: PCR-based typing (PCR-SSOP or PCR-SSP)
Number of subjects: 42160

Group type: EXPERIMENTAL
Intervention: PCR-based typing
Number of subjects: 42160
Study: 9137123

Group type: EXPERIMENTAL
Intervention: Clomipramine (200 mg i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study: 8498465

Group type: EXPERIMENTAL
Intervention: Life review reminiscence activities
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 24
Study: 3479848

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 50
Study: 31436231

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous RFA plus intravenous infusion of LTLD (combination group, n = 11)
Number of subjects: 18

Group type: COMPARATOR
Intervention: RFA plus IV dummy (RFA group, n = 11)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Comparison of coagulation volume
Number of subjects: 18
Study: 28688239

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (n = 13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-plasmapheresis (n = 15)
Number of subjects: 28
Study: 27086573

Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (GIS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resin-based sealant (RS)
Number of subjects: 40
Study: 24365196

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medical treatment (MT)
Number of subjects: 57
Study: 23082846

Group type: EXPERIMENTAL
Intervention: ProDisc-L total disc replacement (TDR)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Circumferential arthrodesis (fusion)
Number of subjects: 236
Study: 19943947

Group type: EXPERIMENTAL
Intervention: Nicotine 4 mg gum or nicotine 10 mg inhaler
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 17378202

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) for TG
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) for TC
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) for LDL-C
Number of subjects: 54
Study: 15250817

Group type: EXPERIMENTAL
Intervention: Empirically Supported Therapies (ESTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trial (RCT) methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reporting practices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative methodologies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing intervention strategies and theories of change
Number of subjects: 0
Study: 11675905

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg tablet daily for 5 days)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tablets three times daily for 7 days)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 575

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 575
Study: 9041571

Group type: EXPERIMENTAL
Intervention: Propofol (3 mg.kg‐1)/propofol bolus (0.5 mg.kg‐1 every 3 min)
Number of subjects: 100
Study: 7705855

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon alpha-2a plus podophyllin 25% W/V administered twice per week, preceded by IFN alpha-2a three times weekly for one week
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo plus podophyllin 25% W/V administered in the same schedule
Number of subjects: 124
Study: 3311619

Group type: EXPERIMENTAL
Intervention: Estrostep (new graduated estrogen formulation)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Loestrin 1/20, Loestrin 1.5/30, Norlestrin 1/50 (constant-dosed oral contraceptives)
Number of subjects: 426

Group type: COMPARATOR
Intervention: All four combination oral contraceptives
Number of subjects: 426
Study: 29685614

Group type: EXPERIMENTAL
Intervention: Online nutrition training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 27400002

Group type: EXPERIMENTAL
Intervention: Delayed physician rounding (8-10 AM)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Early physician rounding (5-7 AM)
Number of subjects: 152
Study: 25138784

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22106360

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Baseline PQ-interval >180 ms
Number of subjects: 1415

Group type: COMPARATOR
Intervention: %VP
Number of subjects: 1415

Group type: COMPARATOR
Intervention: Minimal-paced programmed AVI ≤ 100 ms
Number of subjects: 1415
Study: 20042923

Group type: EXPERIMENTAL
Intervention: Flexible nonlinear (FNL) periodized weight training program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonlinear (NL) periodized weight training program
Number of subjects: 16
Study: 18053306

Group type: EXPERIMENTAL
Intervention: Potassium citrate (30 mmol K-cit/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Potassium chloride
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 15927989

Group type: EXPERIMENTAL
Intervention: Rho-kinase inhibitor fasudil
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 26

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 26
Study: 12030694

Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program (IHDP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10407221

Group type: EXPERIMENTAL
Intervention: Anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Triptorelin administration for 5 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 18
Study: 7562292

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum colonization
Number of subjects: 17

Group type: COMPARATOR
Intervention: Uncolonized neonates
Number of subjects: 17
Study: 2147527

Group type: EXPERIMENTAL
Intervention: 60 mg/day toremifene
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 240 mg/day toremifene
Number of subjects: 50

Group type: COMPARATOR
Intervention: 40 mg/day tamoxifen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no treatment mentioned)
Number of subjects: 50
Study: 6998794

Group type: EXPERIMENTAL
Intervention: Trithiozine (1200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30983457

Group type: EXPERIMENTAL
Intervention: Topical ethyl chloride anesthetic spray
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1% lidocaine subdermal injection
Number of subjects: 120
Study: 31823822

Group type: EXPERIMENTAL
Intervention: Combined treatment with methotrexate (MTX) and zoledronic acid (ZOL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Zoledronic acid (ZOL) monotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 66
Study: 27658483

Group type: EXPERIMENTAL
Intervention: ABT-436
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 25938628

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 901

Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 901
Study: 24260254

Group type: EXPERIMENTAL
Intervention: Conditioned group (desloratadine 5mg + CS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sham-conditioned group (placebo + CS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Natural history group
Number of subjects: 62
Study: 21272321

Group type: EXPERIMENTAL
Intervention: State mandates for colorectal cancer screening coverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: No state mandates for colorectal cancer screening coverage
Number of subjects: 0
Study: 20193338

Group type: EXPERIMENTAL
Intervention: Thalidomide (50 mg p.o. bid) administered on days 1 to 5 after the start of chemotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (ramosetron 0.3 mg i.v. and metoclopramide 20 mg i.m. 30 min prior to chemotherapy)
Number of subjects: 61
Study: 17426226

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15083445

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (n=13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment (n=12)
Number of subjects: 25
Study: 11535548

Group type: EXPERIMENTAL
Intervention: 60 mg/day raloxifene
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 600 mg/day raloxifene
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Raloxifene (both dosages)
Number of subjects: 143
Study: 9500490

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg administered 2 hours before oral contraceptive on pill day 6
Number of subjects: 20

Group type: COMPARATOR
Intervention: No fluconazole (control)
Number of subjects: 20
Study: 7632414

Group type: EXPERIMENTAL
Intervention: Fundic mobilization in Nissen fundoplication
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Standard Nissen fundoplication without fundic mobilization
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 2507747

Group type: EXPERIMENTAL
Intervention: Isocaloric high protein diet (16‐22% protein)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal diet with placebo
Number of subjects: 5
Study: 341939

Group type: EXPERIMENTAL
Intervention: Mianserin hydrochloride
Number of subjects: 0
Study: 29793550

Group type: EXPERIMENTAL
Intervention: ipsilateral tilt position
Number of subjects: 237

Group type: COMPARATOR
Intervention: supine position
Number of subjects: 237
Study: 27737678

Group type: EXPERIMENTAL
Intervention: Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Helium postconditioning (15 min of helium)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Helium pre‐ and postconditioning
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 125
Study: 24436209

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: US and CT
Number of subjects: 40
Study: 22179454

Group type: EXPERIMENTAL
Intervention: Roux-en-Y (R-Y) anastomosis
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 159

Group type: COMPARATOR
Intervention: Billroth I (B-I) anastomosis
Number of subjects: 159

Group type: COMPARATOR
Intervention: Billroth II (B-II) with Braun anastomosis
Number of subjects: 159

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 159
Study: 20456248

Group type: EXPERIMENTAL
Intervention: 50 U/ml NT 201 dilution
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 20 U/ml NT 201 dilution
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both dilutions of NT 201
Number of subjects: 192
Study: 18827325

Group type: EXPERIMENTAL
Intervention: 2 minutes of passive stretching
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 minutes of passive stretching
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8 minutes of passive stretching
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control with no stretching
Number of subjects: 12
Study: 15943834

Group type: EXPERIMENTAL
Intervention: Thyroid autoantibodies (TPO‐Ab, Tg‐Ab)
Number of subjects: 4649
Study: 12528021

Group type: EXPERIMENTAL
Intervention: Hypothermia (32-33 degrees C)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 28
Study: 10227008

Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐oestradiol + 2.5, 5, 10 or 15 mg dydrogesterone (orally once a day)
Number of subjects: 102